TOUCHSTONE

October 20, 2017October 20, 2017

Ozanimod Results Promising in Crohn’s Disease, Ulcerative Colitis, Phase 2 Trial Data Show

News

Celgene recently presented positive data from two Phase 2 studies — the STEPSTONE and TOUCHSTONE studies — for the company’s investigational compound ozanimod (RPC-1063) as a therapy for Crohn’s disease and ulcerative colitis ... Read more

March 24, 2016May 17, 2016

UC Patients Taking Ozanimod in Phase 2 Trial Show Histologic Improvement, Celegene Reports

News, Ulcerative colitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, has announced the release of additional data on exploratory endpoints from its Phase 2 clinical trial assessing ozanimod in people with moderate to severe ulcerative colitis (UC). The data, ... Read more

October 27, 2015October 27, 2015

Ulcerative Colitis Celgene’s Therapy Ozanimod Shows Promising Results in Phase 2 Trial

News

Celgene Corporation, a biopharmaceutical company focused on the development of innovative therapies for cancer and immune-inflammatory related diseases, recently announced the results of the “maintenance phase” of its Phase 2 ... Read more

July 17, 2015July 17, 2015

Celgene to Acquire Receptos, Advancing the Potential of Ozanimod for the Treatment of Ulcerative Colitis

News, Ulcerative colitis

This week Celgene Corporation, a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein ... Read more

April 22, 2015September 28, 2016

Receptos Announces Positive Results for Ulcerative Colitis Therapy in Maintenance Period of Phase 2 Trial

Ulcerative colitis

Receptos, Inc. a biopharmaceutical company that develops drug candidates for the treatment of immune and metabolic diseases, recently announced positive results for the maintenance period of TOUCHSTONE, a Phase 2 clinical ... Read more

October 28, 2014September 28, 2016

MS Drug Candidate May Also Treat Ulcerative Colitis

News, Ulcerative colitis

Receptos, Inc., a San Diego-based biotechnology company, announced promising new clinical data for its drug candidate RPC1063 for ulcerative colitis. The drug was first discovered and synthesized at The Scripps Research Institute (TSRI) by ... Read more